glp-1 and general anesthesia Anesthetic Considerations for Patients Taking Glucagon-Like Peptide-1 Agonists New Study Recommends Stopping GLP-1

These injections can boost energy levels, improve cognitive function, and support overall health

Get a new prescription or refill of Farxiga today from a board-certified primary care doctor online.* About Farxiga Farxiga is considered a sodium-glucose cotransporter 2 (SGLT2) inhibitor, which functions by aiding the kidneys in removing glucose from the body through urine

The Wegovy label reports a randomized withdrawal trial in which patients who reached 2.4 mg after a 20-week run-in either continued or switched to placebo

Results vary from person to person, but by providing your body with the tools it needs, you are setting the stage for a healthier future

A 2025 intravenous safety study involving two healthy adults found infusions up to 20 mg well tolerated, with no adverse events or clinically meaningful changes in vital signs or laboratory biomarkers